This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfil…

Locally Advanced (Unresectable) or Metastatic Solid Tumors

~Estimated

~$10 – $8,750

NEOK Bio, Inc.NCT07612176

Phase 1

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill…

Locally Advanced (Unresectable) or Metastatic Solid Tumors

~Estimated

~$10 – $8,750

NEOK Bio, Inc.NCT07612189